⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3881071 | 0.98 | CYP1A1 (0.43) | — | |
| Cyanide SCHEMBL28133661 | 0.94 | CYP1A1 (0.41) | — | |
| Formic Acid SCHEMBL28134510 | 0.88 | MKNK2 (0.41) | — | |
| SCHEMBL4441012 | 0.88 | CYP3A4 (0.38) | — | |
| SCHEMBL5848746 | 0.86 | CYP1A1 (0.47) | — | |
| SCHEMBL1557265 | 0.84 | LTA4H (0.45) | — | |
| SCHEMBL3957255 | 0.82 | CHRNB2 (0.43) | — | |
| SCHEMBL744752 | 0.82 | CYP1A1 (0.61) | — | |
| SCHEMBL7453614 | 0.80 | POLB (0.41) | — | |
| SCHEMBL2953529 | 0.80 | SMN1; SMN2 (0.49) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1422 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-115869923-B | Oxygen absorbing material, preparation method thereof and prepared adsorption material capable of simultaneously adsorbing oxygen and organic solvent | 威格科技(苏州)股份有限公司 | 2024-03-22 | — | — | CN | claimed |
| CN-115869923-A | Oxygen absorbing material, preparation method thereof and prepared adsorbing material capable of adsorbing oxygen and organic solvent simultaneously | 威格科技(苏州)股份有限公司 | 2023-03-31 | — | — | CN | claimed |
| CN-111548349-A | RET kinase inhibitor intermediate and preparation method thereof | 厦门云凡医药科技有限公司 | 2020-08-18 | — | — | CN | claimed |
| WO-2009018367-A2 | NOVEL SALT FORMS OF (2S)-(4E)-N-METHYL-5-[3-(5-METHOXYPYRIDIN)YL]-4-PENTEN-2-AMINE | TARGACEPT, INC. (US) | 2009-02-05 | — | — | WO | claimed |
| US-20260138987-A1 | MUSCARINIC ACETYLCHOLINE M1 RECEPTOR ANTAGONISTS | CONTINEUM THERAPEUTICS INC (US) | 2026-05-21 | — | — | US | disclosed |
| EP-4724443-A1 | PYRAZOLO-PYRIMIDINONE COMPOUNDS FOR USE IN METHODS OF INHIBITING WEE1 A KINASE | Acrivon Therapeutics, Inc. (US) | 2026-04-15 | — | — | EP | disclosed |
| US-20260076975-A1 | TPK AGONIST AND METHOD FOR USING SAME TO TREAT NEURODEGENERATIVE DISEASES | SHANGHAI RAISING PHARMACEUTICAL CO LTD (CN) | 2026-03-19 | — | — | US | disclosed |
| US-12565501-B2 | Muscarinic acetylcholine M1 receptor antagonists | CONTINEUM THERAPEUTICS, INC. (US) | 2026-03-03 | — | — | US | disclosed |
| US-20260042759-A1 | INHIBITOR CONTAINING BICYCLIC DERIVATIVE, PREPARATION METHOD THEREFOR AND USE THEREOF | SHANGHAI HANSOH BIOMEDICAL CO LTD (CN) | 2026-02-12 | — | — | US | disclosed |
| EP-4688778-A1 | 1H-PYRROLO[2,3-B]PYRIDIN-4-YL]-2-OXOPYRROLIDINE-3-CARBONITRILE DERIVATIVES AS TYROSINE KINASE 2 (TYK2) INHIBITORS FOR THE TREATMENT OF INFLAMMATORY DISEASES | Biogen MA Inc. (US) | 2026-02-11 | — | — | EP | disclosed |
| EP-3891149-B1 | RET INHIBITORS, PHARMACEUTICAL COMPOSITIONS AND USES THEREOF | SUNSHINE LAKE PHARMA CO LTD (CN) | 2026-01-28 | — | — | EP | disclosed |
| US-12528822-B2 | Cycloalkane-1,3-diamine derivative | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2026-01-20 | — | — | US | disclosed |
| WO-1997040011-A1 | PHARMACEUTICAL COMPOSITIONS FOR PREVENTION AND TREATMENT OF CENTRAL NERVOUS SYSTEM DISORDERS | R. J. REYNOLDS TOBACCO COMPANY (US) | 1997-10-30 | — | — | WO | disclosed |
| US-5629325-A | TREATMENT OF NERVOUS SYSTEM DISORDERS; NEURONAL NICOTINIC CHOLINERGIC COMPOUNDS | ABBOTT LABORATORIES (US) | 1997-05-13 | — | — | US | disclosed |
| US-5616716-A | (3-(5-ethoxypyridin)yl)-alkenyl 1 amine compounds | TARGACEPT, INC. | 1997-04-01 | — | — | US | disclosed |
| WO-1996040682-A1 | 3-PYRIDYLOXYALKYL HETEROCYCLIC ETHER COMPOUNDS USEFUL IN CONTROLLING CHEMICAL SYNAPTIC TRANSMISSION | ABBOTT LABORATORIES (US) | 1996-12-19 | — | — | WO | disclosed |
| US-5346906-A | Enhancement of cholinergic transmitters in treatment of neurological and mental disorders such as Alzheimer's | MERCK SHARPE & DOHME LTD. (GB) | 1994-09-13 | — | — | US | disclosed |
| CN-1087907-A | Heteroaryl naphthalene as white (cell) triolefin biosynthesis inhibitor | MERCK FROSST CANADA INC (CA) | 1994-06-15 | — | — | CN | disclosed |
| EP-0412798-A2 | Substituted pyridines, their preparation, formulations and use in dementia | MERCK SHARP & DOHME LTD. (GB) | 1991-02-13 | — | — | EP | disclosed |
| US-4713080-A | OXIDATIVE COLORING | WELLA AKTIENGESELLSCHAFT (DE) | 1987-12-15 | — | — | US | disclosed |